DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Dalmia Bharat Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·6 Oct 2026, 5:05 pm

Dalmia Bharat

Dalmia Bharat Limited has informed stock exchanges that it has obtained a certificate under the SEBI (Depositories and Participants) Regulations, 2018. This certificate confirms that the company has complied with the regulatory requirements for its depository participants, which are entities that facilitate the holding and transfer of securities in electronic form.

This development is a routine compliance measure and does not indicate any new financial activity or operational change. For investors, it serves as a standard regulatory update that reinforces the company's adherence to market rules. It is a non-event that ensures the smooth functioning of the company's shareholding and transfer processes.

Investors should monitor the company's future compliance filings and any other regulatory announcements. Since this is a procedural update, it is unlikely to have an immediate impact on the stock's price. Watch for any broader market news or company-specific developments that might influence the stock's performance.